LEERINK
CENTER FOR PHARMACOECONOMICS

The Opportunity for Innovation in Primary Progressive Multiple Sclerosis



Published on: August 20, 2026

> A value-centric framework around the broader progress that innovation could deliver patients, caregivers, health systems, and society.

In this Center for Pharmacoeconomics Spotlight, we quantify the impact of primary progressive multiple sclerosis (PPMS) on patient health, caregiver time, healthcare utilization, and workforce participation to estimate the societal value that could be created if innovation could restore outcomes among people living with PPMS to those of the general US population.

Closing the gaps in outcomes between a person living with PPMS treated with best supportive care and a person from the general population has the potential to:

- Create $4-$13 million in value from improved health per person living with PPMS.
- Free up $475,000 worth of caregiver time per person living with PPMS.
- Avoid $250,000 in disease-related healthcare costs per person living with PPMS.
- Produce $500,000 in additional labor production per person living with PPMS.

Safe and effective therapeutics in PPMS can unlock substantial value for patients, caregivers, health systems, and society. The value created by a safe and effective therapeutic for PPMS can extend well beyond its market exclusivity period.

This report is not about the reimbursement or pricing of specific therapeutics but about the broader progress that innovation in PPMS could deliver for patients, caregivers, health systems, and society. Understanding the magnitude and duration of this progress can help inform whether an innovation will ultimately be “worth it” to society.

For details on obtaining full access to the report, contact us via email at cpe@medacorp.com.

The Leerink Center for Pharmacoeconomics is a division of MEDACorp and an affiliate of Leerink Partners

Leerink Center for Pharmacoeconomics

- Melanie Whittington, PhD, Managing Director, Head of the Center for Pharmacoeconomics

Contributors:

Melanie Whittington

Center for Pharmacoeconomics

Disclosures:

This information (including, but not limited to, prices, quotes, and statistics) has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and the information and any opinions contained herein are as of the date of this material and the Firm does not undertake any obligation to update them. The information is not an offer to sell or a solicitation to buy any product to which this information relates. Leerink Partners LLC ("Firm"), its officers, directors, employees, proprietary accounts, and affiliates may have a position, long or short, in the securities referred to in this report, and/or other related securities, and from time to time may increase or decrease the position or express a view that is contrary to that contained in this piece. The Firm's research analysts, bankers, salespeople, and traders may provide oral or written market commentary or trading strategies that are contrary to opinions expressed, and the Firm's market making desk may make investment decisions that are inconsistent with the opinions expressed in this document. The past performance of securities does not guarantee or predict future performance. This material does not take into account individual circumstances, objectives, or needs and is not intended as a recommendation to any particular person(s). As such, the financial instruments discussed herein may not be suitable for all investors, and investors must make their own investment decisions based upon their specific investment objectives and financial situation. This material is a marketing communication and is not and should not be construed as investment research or a research report prepared by a research analyst. Any views portrayed in this material may differ from those of the research department of Leerink Partners LLC. All information contained herein is intended solely for your own personal, informational use, and you are not permitted to reproduce, retransmit, disseminate, sell, license, distribute, republish, broadcast, post, circulate or commercially exploit the information in any manner or media without the express written consent of Leerink Partners LLC, or to use the information for any unlawful purpose. Additional information is available upon request by contacting the Editorial Department, Leerink Partners LLC, 53 State Street, 40th Floor, Boston, MA 02109.MEDACorp LLC (MEDACorp), an affiliate of Leerink Partners LLC, is a global network of independent healthcare professionals (Key Opinion Leaders and consultants) providing industry and market insights to Leerink Partners and its clients.© 2024 Leerink Partners LLC. All Rights Reserved.
Member FINRA/SIPC